Choosing the Right Blood Pressure Medication: A Complete Patient Guide to Treating Primary (Essential) Hypertension

Table of Contents

• Key Points
• Introduction: Why This Matters
• Background: Understanding Hypertension and Its Treatment
• How These Recommendations Were Developed
• Initial Drug Therapy: Where Treatment Begins
• Starting with One Drug (Monotherapy)
• Starting with Two Drugs (Combination Therapy)
• Comparing the Main Drug Classes
• Thiazide vs. Thiazide-Like Diuretics: What's the Difference?
• Key Findings: What the Research Shows
• Patients with Other Medical Conditions (Comorbidities)
• Drug Combinations to Avoid
• Dose Titration and Monitoring
• Clinical Implications: What This Means for Patients
• Limitations of the Research
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• The degree of blood pressure lowering matters more than the specific drug class for preventing heart attacks and strokes.
• Starting with two medications is recommended when blood pressure is 10-20 mmHg above goal; single-pill combinations improve adherence.
• An ACE inhibitor plus a calcium channel blocker was superior to an ACE inhibitor plus a thiazide diuretic in the ACCOMPLISH trial.
• Chlorthalidone and indapamide lower systolic pressure 3.6-5.1 mmHg more than hydrochlorothiazide and last longer.
• Avoid combining an ACE inhibitor with an ARB, as it causes adverse cardiovascular and kidney events.

Introduction: Why This Matters

Hypertension—commonly known as high blood pressure—is a global health crisis. In the United States alone, among nonpregnant adults, treating hypertension is the most common reason for an office visit to a doctor, and it's the most frequent reason for taking a chronic prescription medication.

For decades, doctors have debated which blood pressure medication is "best." But this article from UpToDate—written by leading experts in hypertension—makes a crucial point: the intensity of treatment (the number of medications and their doses) matters more than the choice of any single drug.

In other words, how aggressively you lower blood pressure is more important than which specific pill you take. That said, certain drug classes do offer special benefits for patients with particular health conditions, and some combinations work better than others. This guide walks you through everything you need to know.

Background: Understanding Hypertension and Its Treatment

Blood pressure is measured in millimeters of mercury (mmHg) and recorded as two numbers: systolic pressure (the top number, when your heart beats) and diastolic pressure (the bottom number, when your heart rests between beats).

When blood pressure stays high over time, it damages blood vessels throughout the body, increasing the risk of heart attack, stroke, kidney failure, and other serious conditions. The goal of treatment is to lower blood pressure enough to prevent these complications.

Decades of research have shown that the degree of blood pressure lowering is the main driver of benefit. For the vast majority of patients, reducing blood pressure by a certain amount produces similar protection against cardiovascular disease regardless of which medication class achieves that reduction.

The experts from UpToDate note some important nuances: certain drug classes work better than others in patients with specific coexisting conditions (comorbidities), such as heart failure or kidney disease. But for the average patient, the most important thing is simply getting blood pressure down to a healthy level—and keeping it there.

How These Recommendations Were Developed

This article is not a single study but rather a comprehensive clinical guideline written by three experts in the field: Johannes FE Mann, MD; John M Flack, MD, MPH, FAHA, FASH, MACP; and section editors George L Bakris, MD, and William B White, MD. The content was reviewed by a deputy editor, John P Forman, MD, MSc.

The recommendations are based on a thorough review of the medical literature, which was current through April 2023. The article was last updated on May 4, 2023.

The authors draw on evidence from numerous clinical trials and meta-analyses, including landmark studies such as the ACCOMPLISH trial (Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension), the ALLHAT trial (Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial), and many others. They also align their recommendations with major professional guidelines, including those from the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), and the European Society of Hypertension (ESH).

It's important to understand that this is a peer-reviewed, evidence-based clinical resource designed to help doctors make informed treatment decisions. This patient version explains those recommendations in plain language while preserving all of the key data.

Initial Drug Therapy: Where Treatment Begins

Before any medication is prescribed, the experts are unanimous: every patient with hypertension should first be prescribed nonpharmacologic (lifestyle) therapy. This includes dietary changes, salt restriction, potassium intake management, weight loss if overweight or obese, and regular exercise. These lifestyle measures are the foundation upon which drug therapy is built.

But for many patients, lifestyle changes alone aren't enough. The question then becomes: should treatment start with one drug (monotherapy) or two drugs (combination therapy)? The answer depends on how high your blood pressure is above your target goal.

The UpToDate authors provide a clear framework for making this decision:

Starting with One Drug (Monotherapy)

Monotherapy is recommended for patients with stage 1 hypertension—defined as a systolic pressure of 130 to 139 mmHg and/or diastolic pressure of 80 to 89 mmHg—who have been selected for drug therapy. Some experts also start with one drug when the systolic pressure is 140 to 149 mmHg but the diastolic pressure is below 90 mmHg.

Monotherapy is also the preferred starting point for certain patients at higher risk of side effects from blood pressure medications. These higher-risk patients include:

• People adhering to a very low salt intake
• People who are underweight or frail
• People with a known orthostatic decline in blood pressure (a drop in blood pressure when standing up)
• People with a history of multiple drug allergies or intolerances

Regardless of whether treatment begins with one or two drugs, the initial drug dose should generally be low. There is one notable exception to this rule: angiotensin receptor blockers (ARBs). These medications do not cause severe dose-related side effects, and their maximal antihypertensive effect is moderate in most patients. Therefore, starting with a moderate to high dose of an ARB is reasonable and prevents the need for unnecessary dose titration (gradual adjustment of the dose).

Here's a critically important point for patients: whether you start with one drug or two, the single most important strategy for achieving blood pressure control is avoiding "therapeutic inertia."

What is therapeutic inertia? It's the failure of a doctor to initiate or adjust/intensify prescribed drug therapy even when your blood pressure is recognized as uncontrolled. This is a bigger problem than you might think.

The data are striking: a nationally representative survey of ambulatory primary care practices in the United States found that when blood pressure was above 140/90 mmHg, treatment was intensified with a prescription of a new drug at only 17 percent of office visits. In other words, more than 80 percent of the time, when patients came in with high blood pressure, no medication change was made.

This problem of therapeutic inertia actually has a greater impact on inadequate hypertension control than patients failing to take their prescribed medications. So if your blood pressure isn't controlled, don't be afraid to speak up and ask your doctor whether your treatment should be adjusted.

Which Drug for Monotherapy?

The three primary options for antihypertensive drug therapy in most patients are:

1. An ACE inhibitor (angiotensin-converting enzyme inhibitor) or ARB (angiotensin receptor blocker)
2. A calcium channel blocker
3. A thiazide diuretic (preferably a thiazide-like diuretic)

If there are no compelling reasons to select a specific drug class, the UpToDate experts suggest treating with an ACE inhibitor (or ARB) or a dihydropyridine calcium channel blocker, rather than a thiazide diuretic.

When used as monotherapy, these four drug classes produce similar benefits on cardiovascular endpoints (heart attacks, strokes, and death from cardiovascular causes). However, the combination of an ACE inhibitor and a dihydropyridine calcium channel blocker may provide superior protection against cardiovascular events compared with a combination of a thiazide diuretic with the same ACE inhibitor.

There's a practical reason for this recommendation. Since the majority of patients who begin treatment with monotherapy will ultimately require additional drugs to control their blood pressure, starting with a medicine that is part of the optimal two-drug combination is a simpler strategy than starting with, for example, a thiazide diuretic and then—when a second drug becomes necessary—switching medications entirely.

The data supporting this approach come from the ACCOMPLISH trial, which will be discussed in more detail below.

Nevertheless, a thiazide diuretic remains a reasonable alternative for monotherapy, and it may actually be preferred over an ACE inhibitor, ARB, or dihydropyridine calcium channel blocker in specific situations:

• Patients with edema (fluid retention/swelling)
• Patients with osteoporosis (thiazides have beneficial effects on bone metabolism)
• Patients with calcium nephrolithiasis with hypercalciuria (calcium-containing kidney stones caused by excess calcium in the urine)

When a thiazide diuretic is used, the experts recommend choosing a thiazide-like diuretic (chlorthalidone or indapamide) rather than hydrochlorothiazide. The evidence for this preference is covered in detail in the section on diuretics below.

Why Beta Blockers Are Not First-Line

In the absence of a compelling indication (such as a recent heart attack), the UpToDate authors and others recommend that beta blockers NOT be used as first-line therapy, particularly in patients over age 60.

The evidence shows that compared with other antihypertensive drugs, beta blockers are associated with:

• Inferior protection against stroke risk
• Inferior protection against all-cause mortality
• Impaired glucose tolerance
• An increased risk of new-onset diabetes

These disadvantages are primarily seen in patients over age 60. There are exceptions: vasodilating beta blockers such as carvedilol and nebivolol do not appear to have the same negative metabolic effects. But for most patients with uncomplicated hypertension, beta blockers should not be the first choice.

Starting with Two Drugs (Combination Therapy)

For patients whose blood pressure is further from their goal, starting with two medications makes sense. The UpToDate guidance is clear:

"In general, patients with a systolic pressure 10 to 20 mmHg above goal and/or a diastolic pressure 10 mmHg above goal should have antihypertensive drug therapy initiated with low to moderate doses of two agents with complementary mechanisms of action."

Some experts begin with two agents in patients with stage 2 hypertension (systolic pressure ≥140 mmHg and/or diastolic ≥90 mmHg), while others prefer to start two drugs when systolic pressure is ≥150 mmHg and/or diastolic is ≥90 mmHg.

Why start with two drugs instead of one?

• Combination therapy lowers blood pressure more than monotherapy
• It increases the likelihood that target blood pressure will be achieved in a reasonable time period
• It allows attainment of goal blood pressure with lower doses of each medication, which reduces the risk of dose-related side effects

This approach is consistent with guidelines from the ACC/AHA and the ESC/ESH.

The Single-Pill Advantage

When starting treatment with two agents, the experts strongly suggest using a single-pill combination—that is, one pill containing both medications—rather than taking two separate pills (known as "free equivalents").

The evidence shows that single-pill combinations lead to:

• Greater blood pressure reduction
• Increased attainment of blood pressure goal
• Better medication adherence (patients are more likely to take one pill than two)

Observational data also suggest that single-pill combination therapy reduces the risk of cardiovascular disease and mortality compared with free equivalents.

When Separate Pills Make More Sense

There are situations where starting with free equivalents (separate pills) is the better choice:

• Patients with a history of multiple drug allergies or intolerances: Starting with one drug and then adding a second agent several weeks later makes it less complicated for the clinician to identify the culprit drug if a side effect occurs.
• Complex cases of hypertension: Free equivalents are easier to titrate when frequent dose adjustment is needed. This applies to patients with renovascular hypertension (high blood pressure caused by narrowing of the kidney arteries) or other secondary forms of hypertension, as well as those with target organ damage such as heart failure or kidney function impairment.

In these situations, once blood pressure is controlled and the patient is tolerating therapy, the free equivalents can often be switched to a single-pill combination for convenience and adherence.

It's also worth noting that single-pill combinations are not always perfect for everyone:

• They are often more expensive
• They may not be covered by prescription drug insurance
• Their availability varies by region

Which Two-Drug Combination is Preferred?

When two drugs are used, they should be from different antihypertensive drug classes. In most patients, the drugs should be selected from among the three preferred classes:

1. ACE inhibitors (or ARBs)
2. Calcium channel blockers
3. Thiazide diuretics (ideally a thiazide-like rather than a thiazide-type diuretic)

For patients without an indication for a non-preferred agent, the UpToDate experts suggest treating with the combination of an ACE inhibitor (or ARB) and a calcium channel blocker, preferably a dihydropyridine calcium blocker.

This recommendation flows from the ACCOMPLISH trial, which we'll examine in the Key Findings section below.

The combination of an ACE inhibitor (or ARB) with a thiazide diuretic is a reasonable alternative, particularly for patients who have conditions that can benefit from a thiazide diuretic (such as edema, osteoporosis, or calcium kidney stones with hypercalciuria). However, a few important notes apply:

• Thiazide-like diuretics (chlorthalidone, indapamide) are preferred over thiazide-type diuretics (hydrochlorothiazide)
• There are only two single-pill combinations available that combine an ACE inhibitor (or ARB) with a thiazide-like diuretic: perindopril-indapamide and azilsartan-chlorthalidone

Treating with a calcium channel blocker and a thiazide diuretic is also a reasonable option, but there are no single-pill combinations of these two classes currently available.

Comparing the Main Drug Classes

Let's take a closer look at each major drug class, how they work, and what patients should know.

ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors)

These drugs work by blocking the conversion of angiotensin I to angiotensin II, a hormone that narrows blood vessels. By reducing angiotensin II levels, ACE inhibitors allow blood vessels to relax and widen, lowering blood pressure.

Common examples include lisinopril, enalapril, ramipril, and perindopril.

ACE inhibitors are especially valuable in patients with:

• Heart failure
• Diabetes with kidney disease (albuminuria)
• After a heart attack (myocardial infarction)

ARBs (Angiotensin Receptor Blockers)

ARBs work similarly to ACE inhibitors but block the action of angiotensin II at a different point in the pathway—at the receptor level. They have a similar effect on blood pressure but generally cause less cough, a common side effect of ACE inhibitors.

Common examples include losartan, valsartan, candesartan, and azilsartan.

As noted earlier, ARBs are unique in that they do not cause severe dose-related side effects, so starting at a moderate to high dose is reasonable.

Calcium Channel Blockers

These drugs prevent calcium from entering the muscle cells of the heart and blood vessels, causing the blood vessels to relax. The dihydropyridine calcium channel blockers (such as amlodipine, nifedipine, and felodipine) primarily affect blood vessels, while non-dihydropyridine calcium channel blockers (such as verapamil and diltiazem) also affect the heart.

Calcium channel blockers are especially useful in elderly patients, patients with isolated systolic hypertension, and patients of African ancestry.

Thiazide Diuretics

These "water pills" work by causing the kidneys to remove excess sodium and water from the body, which reduces blood volume and lowers blood pressure. They also cause blood vessel relaxation.

There are two main types:

• Thiazide-type diuretics: hydrochlorothiazide
• Thiazide-like diuretics: chlorthalidone, indapamide

This distinction matters a great deal, as discussed below in the dedicated section.

Thiazide vs. Thiazide-Like Diuretics: What's the Difference?

This is one of the most detailed and technically specific sections of the original article, and it deserves careful attention because it affects millions of prescriptions.

The UpToDate authors are unequivocal: when a thiazide diuretic is used, chlorthalidone or indapamide (thiazide-like diuretics) are significantly more potent antihypertensive agents than hydrochlorothiazide (a thiazide-type diuretic) at similar dose levels.

The Meta-Analysis Evidence

A meta-analysis of 14 trials compared the blood pressure reduction achieved with one of three dose levels of hydrochlorothiazide (low, intermediate, high) against a similar dose of one of the thiazide-like diuretics. The results were clear:

• Chlorthalidone lowered systolic pressure by 3.6 mmHg more than hydrochlorothiazide
• Indapamide lowered systolic pressure by 5.1 mmHg more than hydrochlorothiazide

These differences are clinically meaningful. A 3.6 to 5.1 mmHg reduction in systolic blood pressure might not sound like much, but at the population level, even small reductions in blood pressure translate into significant reductions in heart attacks, strokes, and deaths.

The Duration of Action Difference

Perhaps even more important than potency is the difference in duration of action:

• Chlorthalidone and indapamide: 24 or more hours of blood pressure-lowering effect
• Hydrochlorothiazide: only 6 to 12 hours

This difference may not affect office blood pressure readings if the medication is taken in the morning (because the effect is measured during the day). But the longer-acting drugs produce a greater fall in nighttime blood pressure, which is important for overall cardiovascular protection.

In one small trial, nighttime blood pressure decreased by 13.5 mmHg with 25 mg/day of chlorthalidone, compared with only 6.4 mmHg with 50 mg/day of hydrochlorothiazide. That's more than double the nighttime blood pressure reduction with the thiazide-like drug at half the dose.

The Veteran's Affairs Trial: A Head-to-Head Comparison

The two drugs were directly compared in a large trial involving 13,523 older male veterans (mean age 72 years) who had uncontrolled hypertension (mean systolic pressure 139 mmHg) despite taking hydrochlorothiazide 25 mg daily. Of these patients, 87 percent were also taking other antihypertensive agents, while 13 percent were taking hydrochlorothiazide alone.

Patients were randomly assigned to either continue hydrochlorothiazide or switch to 12.5 mg of chlorthalidone. The results after 2.4 years of follow-up:

• Rates of all-cause mortality, stroke, myocardial infarction, and hospitalization for heart failure were the same in each group
• Blood pressure was also similar between the groups—and importantly, remained uncontrolled throughout the trial in both groups
• Low potassium (serum potassium ≤3 mEq/L) occurred in 5 percent of those taking chlorthalidone and 3.6 percent of those taking hydrochlorothiazide

At first glance, this might seem to argue that the two drugs are equivalent. But the UpToDate authors point out several serious limitations with this trial that should make patients and doctors cautious about drawing that conclusion.

Why the Veteran's Trial Results Might Be Misleading

The primary problem: the wrong dose was used. When a patient has uncontrolled blood pressure despite taking 25 mg of hydrochlorothiazide, the standard approach would be to switch the patient to 25 mg of chlorthalidone—not 12.5 mg. The 12.5 mg dose is half the dose that was used in major cardiovascular outcome trials, such as ALLHAT.

High crossover rates: More than 15 percent of patients assigned to chlorthalidone switched back to hydrochlorothiazide during the trial, whereas only 4 percent switched from hydrochlorothiazide to chlorthalidone. This asymmetry could have biased the results toward showing no difference (toward the null).

Why did so many patients switch? The authors speculate that it may be because chlorthalidone tablets are not available in a 12.5 mg pill and are typically not scored (not grooved for splitting), forcing patients to split their tablets—a cumbersome and potentially imprecise process.

The Bigger Picture: What Other Studies Show

Other studies, including several network meta-analyses, have concluded that cardiovascular outcomes were superior with chlorthalidone compared with hydrochlorothiazide.

By contrast, some retrospective observational studies suggest that the two drugs lead to similar rates of cardiovascular events but that chlorthalidone increases the risk of adverse metabolic effects (such as hypokalemia—low potassium).

However, there's an important mitigation strategy: the metabolic derangements associated with chlorthalidone can be attenuated, at least in part, by pairing it with an ACE inhibitor or an ARB. This is one reason why the combination of an ACE inhibitor plus a thiazide-like diuretic is a commonly used and effective treatment strategy.

Key Findings: What the Research Shows

Let's consolidate the major findings from the evidence base referenced in this article:

1. The ACCOMPLISH Trial: ACE Inhibitor + Calcium Channel Blocker Wins

The ACCOMPLISH trial (Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension) provides critical evidence for choosing between two-drug combinations.

The trial compared two combinations in patients with systolic hypertension:

• An ACE inhibitor (benazepril) combined with a dihydropyridine calcium channel blocker (amlodipine)
• The same ACE inhibitor (benazepril) combined with a thiazide diuretic (hydrochlorothiazide)

The result was clear: the combination of an ACE inhibitor and a dihydropyridine calcium channel blocker provided superior protection against cardiovascular events compared with the combination of the ACE inhibitor and the thiazide diuretic.

This is why the UpToDate authors recommend the ACE inhibitor (or ARB) + calcium channel blocker as the preferred initial combination therapy for most patients.

2. Therapeutic Inertia is a Major Problem

As highlighted earlier, a nationally representative survey of ambulatory primary care practices found that when blood pressure was above 140/90 mmHg, treatment was intensified with a new drug prescription at only 17 percent of office visits. This means 83 percent of visits with uncontrolled hypertension resulted in no treatment change.

This fundamental finding underscores the importance of patients being active participants in their own care. If your blood pressure is consistently above goal, don't assume that "wait and see" is the right approach—ask your doctor about adjusting your treatment.

3. Beta Blockers Are Weaker at Preventing Stroke

Compared with other antihypertensive drugs, beta blockers appear to be associated with inferior protection against stroke risk and all-cause mortality. These disadvantages are primarily seen in patients over age 60.

Beta blockers are also associated with impaired glucose tolerance and an increased risk of new-onset diabetes. The exceptions are vasodilating beta blockers such as carvedilol and nebivolol, which do not appear to carry the same metabolic risks.

4. Chlorthalidone and Indapamide Are More Potent Than Hydrochlorothiazide

From the meta-analysis of 14 trials:

• Chlorthalidone lowers systolic pressure by an additional 3.6 mmHg
• Indapamide lowers systolic pressure by an additional 5.1 mmHg

Both thiazide-like diuretics also last much longer in the body (24+ hours vs. 6-12 hours for hydrochlorothiazide), providing better nighttime blood pressure control.

5. Single-Pill Combinations Improve Adherence

Multiple studies confirm that single-pill combinations (both drugs in one pill) lead to:

• Greater blood pressure reduction
• Increased attainment of blood pressure goal
• Better medication adherence

Observational data suggest that single-pill combination therapy reduces the risk of cardiovascular disease and mortality compared with taking the same drugs as separate pills.

Patients with Other Medical Conditions (Comorbidities)

Some patients have compelling reasons to use a specific drug class based on their other medical conditions. The original article references a detailed table that guides these decisions. Here are the key situations where specific drug classes are preferred:

• Heart failure with preserved ejection fraction: Mineralocorticoid receptor antagonists (spironolactone, eplerenone) have special benefits
• After a myocardial infarction (heart attack): Beta blockers are recommended because they reduce the risk of future cardiovascular events
• Diabetes with kidney disease (albuminuria): ACE inhibitors or ARBs are preferred because they protect kidney function
• Edema (fluid retention): Thiazide diuretics help reduce swelling
• Osteoporosis: Thiazide diuretics have beneficial effects on bone metabolism by reducing calcium loss in urine
• Recurrent calcium kidney stones (calcium nephrolithiasis with hypercalciuria): Thiazide diuretics reduce calcium excretion in urine, helping prevent stone formation

If you have any of these conditions, your doctor may choose a medication that is different from what would be prescribed for a patient without those conditions. This is called a "compelling indication."

Drug Combinations to Avoid

Not all drug combinations are safe or effective. In fact, one combination in particular is explicitly warned against:

Patients should NOT simultaneously be prescribed both an ACE inhibitor and an ARB.

Combining these two drugs is associated with adverse cardiovascular and kidney events. Despite both drugs targeting the same blood pressure pathway (the renin-angiotensin system), combining them does not add meaningful benefit but does add harm.

This warning is consistent across multiple guidelines and is reinforced in several specific clinical contexts, including diabetes and chronic kidney disease. If you are currently taking both an ACE inhibitor and an ARB, you should discuss this with your doctor—there may be a safer alternative.

Dose Titration and Monitoring

The original article references detailed guidance on dose titration and monitoring, which is discussed in other sections of the UpToDate resource. The key principles are:

1. Start at a low dose
2. Adjust (titrate) the dose based on blood pressure response and tolerance
3. Add a second medication if blood pressure remains uncontrolled on the maximum tolerated dose of the first medication
4. Monitor regularly to confirm blood pressure control and check for side effects
5. Check laboratory values as appropriate (potassium, kidney function, etc.) depending on which medications are used

The most important message is this: avoid therapeutic inertia. If your blood pressure isn't at goal, your treatment should be adjusted—whether that means increasing the dose, adding a new medication, or switching to a different class.

Clinical Implications: What This Means for Patients

This comprehensive review has several practical implications for patients living with hypertension.

First, the most important thing is lowering your blood pressure—period. The specific medication matters less than the degree of blood pressure reduction. So don't get too caught up in which drug you're taking; focus on whether your blood pressure is actually at goal.

Second, if your blood pressure is significantly above goal (more than 10-20 mmHg systolic above target), two medications are better than one. Starting with combination therapy gets you to goal faster and with fewer side effects than a single medication at a high dose.

Third, ask about single-pill combinations. If you need two medications, taking one pill that contains both drugs dramatically improves adherence. This matters because observational data show that single-pill combinations reduce the risk of cardiovascular disease and death compared with taking two separate pills.

Fourth, if you need a diuretic, ask if a thiazide-like diuretic (chlorthalidone or indapamide) might be better for you than hydrochlorothiazide. The evidence shows these drugs are more potent and last longer. However, they also carry a slightly higher risk of low potassium (hypokalemia), but this can be managed by combining with an ACE inhibitor or ARB and by monitoring blood tests.

Fifth, if you're over 60 and taking a beta blocker as your only blood pressure medication, ask your doctor whether it's the best choice for you. Beta blockers are clearly beneficial after a heart attack and in heart failure, but for uncomplicated hypertension in older adults, other drug classes provide better stroke protection.

Sixth, never take both an ACE inhibitor and an ARB together. If you are, talk to your doctor about switching.

Seventh, be your own advocate. The fact that treatment was intensified at only 17 percent of office visits when blood pressure was above 140/90 is a wake-up call. If your blood pressure is consistently high, speak up. Ask your healthcare provider why your treatment hasn't been adjusted and what the plan is to get you to goal.

Limitations of the Research

While the evidence base for antihypertensive therapy is extraordinarily robust, the authors acknowledge several limitations in the specific studies discussed:

Limitations of Chlorthalidone vs. Hydrochlorothiazide Research

The Veteran's Affairs trial that found no difference between chlorthalidone and hydrochlorothiazide was hampered by significant design problems:

• The chlorthalidone dose used (12.5 mg) was half the clinically recommended dose of 25 mg
• More than 15 percent of patients in the chlorthalidone group switched back to hydrochlorothiazide, while only 4 percent switched in the opposite direction—a bias that would tend to obscure any real difference
• Blood pressure remained uncontrolled in both groups throughout the trial, suggesting that the overall treatment intensity was inadequate

Additionally, some retrospective observational studies suggest that chlorthalidone may increase metabolic side effects (including low potassium and possibly higher blood sugar) compared to hydrochlorothiazide, though the authors note these effects can be mitigated by combining chlorthalidone with an ACE inhibitor or ARB.

Limitations of Combination Therapy Research

The experience with "polypill" strategies—initiating treatment with more than two antihypertensive agents at once—is limited. While some trials have examined this approach, the evidence base is not yet strong enough to recommend it routinely.

General Limitations of Clinical Guidelines

Clinical guidelines are based on population-level data, and individual responses to medications vary widely. What works best for one patient may not work for another. Race, age, genetics, diet, and coexisting conditions all influence how a person responds to antihypertensive therapy. These guidelines are starting points, not rigid rules.

Recommendations for Patients

Based on this comprehensive review, here are actionable recommendations for patients with hypertension:

1. Don't skip lifestyle changes. Every hypertensive patient should be prescribed nonpharmacologic therapy: reduce salt intake, eat a healthy diet (such as the DASH diet), maintain adequate potassium intake (unless contraindicated), achieve and maintain a healthy weight, and exercise regularly.
2. Know your numbers and your goal. Understand your target blood pressure and whether you're above it. Ask your doctor what your specific goal is, as it may vary based on age and other conditions.
3. If your blood pressure is 10-20 mmHg above goal, ask about starting with two medications. Combination therapy gets you to goal faster and with fewer side effects.
4. Ask for a single-pill combination if you need two medications. It improves adherence, and evidence shows it reduces cardiovascular risk more than separate pills.
5. If you need a diuretic, ask about chlorthalidone or indapamide. These thiazide-like diuretics are more potent and last longer than hydrochlorothiazide, though you may need additional potassium monitoring.
6. If you're over age 60 with uncomplicated hypertension, ask why you're taking a beta blocker. Other classes provide better stroke protection. If you have had a heart attack or have heart failure, a beta blocker may be exactly right for you—but that's a different situation.
7. Never take an ACE inhibitor and an ARB together. This combination increases the risk of kidney and cardiovascular harm.
8. Advocate for treatment adjustment when needed. If your blood pressure remains above goal at multiple visits, ask for a change. Remember, more than 80 percent of visits with uncontrolled hypertension result in no treatment change—but that doesn't mean it's okay. You have the right to ask for better blood pressure control.
9. Take your medications as prescribed. Adherence is one of the most powerful predictors of blood pressure control. If you're having trouble affording medications or remembering to take them, talk to your doctor or pharmacist—there are usually solutions.
10. Monitor at home. Home blood pressure monitoring provides valuable information that office readings can miss, particularly nighttime blood pressure. Consider using a validated home blood pressure monitor and bringing your readings to appointments.

Remember that hypertension is a chronic condition that requires ongoing management. It's a marathon, not a sprint. Find a healthcare provider who takes your blood pressure seriously, educate yourself, and take an active role in your treatment. The evidence is clear: achieving blood pressure control dramatically reduces the risk of heart attack, stroke, kidney failure, and premature death.

Frequently Asked Questions

What is the most important factor in choosing a blood pressure medication?

The most important factor is how much your blood pressure is lowered, not which specific drug you take. Lowering blood pressure significantly reduces the risk of heart attack, stroke, and death. For most patients, different drug classes provide similar protection if they achieve the same blood pressure reduction.

Should I start with one blood pressure pill or two?

It depends on how high your blood pressure is above your goal. If your systolic pressure is 10 to 20 mmHg above goal or your diastolic pressure is 10 mmHg above goal, starting with two medications is recommended. Two drugs lower blood pressure more effectively and often with fewer side effects than one high-dose pill.

What is a single-pill combination and why is it recommended?

A single-pill combination contains two blood pressure medications in one tablet. Taking one pill improves medication adherence and leads to better blood pressure control. Observational data suggest it may also reduce the risk of cardiovascular disease and death compared with taking the same drugs as separate pills.

Which two-drug combination is preferred for most patients?

For most patients without a specific reason to choose differently, the preferred combination is an ACE inhibitor (or ARB) plus a calcium channel blocker. This was shown in the ACCOMPLISH trial to provide superior protection against cardiovascular events compared with an ACE inhibitor plus a thiazide diuretic.

Why should beta blockers not be my first blood pressure medicine if I am over 60?

For patients over 60 with uncomplicated hypertension, beta blockers are associated with inferior stroke protection and all-cause mortality compared with other drug classes. They also impair glucose tolerance and increase the risk of new-onset diabetes. Exceptions include vasodilating beta blockers like carvedilol and nebivolol.

Source Information

Original Article Title: Choice of drug therapy in primary (essential) hypertension - UpToDate

Authors: Johannes FE Mann, MD; John M Flack, MD, MPH, FAHA, FASH, MACP

Section Editors: George L Bakris, MD; William B White, MD

Deputy Editor: John P Forman, MD, MSc

Literature Review Current Through: April 2023

Topic Last Updated: May 4, 2023

Source: UpToDate, a peer-reviewed clinical resource widely used by healthcare professionals worldwide.

Note: This patient-friendly article is based on peer-reviewed research and clinical guidelines. It is intended for educational purposes and does not replace professional medical advice. Always consult your healthcare provider before making any changes to your medications.